Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 9, 2026

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Recurrent seminomas: clinical features and biologic implications.

Avik Som1, Rui Zhu, Charles C Guo

  • 1Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

Urologic Oncology
|September 9, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

The New England journal of medicine·2026
Same author

Developing a Clinically Practical Biomaterial Platform for Endogenous Liver Regeneration.

Gels (Basel, Switzerland)·2026
Same author

A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.

Cancer discovery·2026
Same author

FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate.

Histopathology·2026
Same author

Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma.

Radiology·2026
Same author

Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite Instability.

JCO precision oncology·2026
Same journal

Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size-dependent survival in pT3N0M0 clear cell renal cell carcinoma.

Urologic oncology·2026
Same journal

Ipsilateral sampling maintains clinically significant cancer detection and reduces overdiagnosis in PI-RADS 4-5 lesions.

Urologic oncology·2026
Same journal

Testis-sparing surgery for small testicular masses: Functional and oncological outcomes.

Urologic oncology·2026
Same journal

Subcapsular versus total orchiectomy in advanced prostate cancer: A systematic review and meta-analysis of clinical and patient-reported outcomes.

Urologic oncology·2026
Same journal

Featured SUO Fellow: Soum Lokeshwar, MD MBA.

Urologic oncology·2026
Same journal

Automating standardization of prostate cancer biopsy and histopathology reports with privacy-preserving local large language models.

Urologic oncology·2026
See all related articles

Patients with atypical seminoma, characterized by visceral metastases or elevated beta-human chorionic gonadotropin (βHCG), may respond to specific chemotherapy regimens. Biomarker analysis suggests these tumors are distinct from embryonal carcinomas.

Area of Science:

  • Oncology
  • Pathology
  • Medical Research

Background:

  • A subset of seminoma patients exhibit atypical phenotypes, including visceral metastases, elevated beta-human chorionic gonadotropin (βHCG), and recurrent disease, associated with a poor prognosis.
  • Understanding the unique characteristics and potential biomarkers of these rare seminoma subtypes is crucial for improving patient outcomes.

Purpose of the Study:

  • To characterize the clinical features and treatment responses of rare seminoma patients with atypical phenotypes.
  • To investigate potential biomarkers that may distinguish these atypical seminomas as a unique subtype.

Main Methods:

  • Retrospective analysis of 25 patients with seminoma and atypical features (visceral metastases, βHCG >200 mU/ml, recurrent disease).
  • Review of treatment efficacy and clinical outcomes.

More Related Videos

Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Experiment Videos

Last Updated: Jun 9, 2026

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

  • Immunohistochemical analysis of tumor markers (OCT 3/4, PLAP, CD30, TRA-1-60, c-kit, gp200) in 6 patients, compared to classic seminomas and mixed germ-cell tumors.

    • Main Results:

    • Certain chemotherapy regimens, including ifosfamide, paclitaxel, and cisplatin, demonstrated efficacy in treating these atypical seminomas.
    • Immunohistochemical profiles of atypical seminomas resembled classic seminomas and seminoma components of mixed tumors, but differed from embryonal carcinoma components.

    Conclusions:

    • Despite potential chemotherapy resistance, atypical seminomas can respond to specific chemotherapeutic agents.
    • The distinct phenotypes of these atypical seminomas do not appear to be related to embryonal carcinomas, based on pilot biomarker studies.
    • Further research is warranted to validate these preliminary findings and confirm the unique nature of atypical seminomas.